These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30761667)

  • 1. Routine surveillance for symptomatic toxicities with real-time clinician reporting in Danish breast cancer patients-Organization and design of the first national, cluster randomized trial using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Pappot H; Baeksted C; Knoop A; Mitchell SA; Nissen A; Johansen C
    Breast J; 2019 Mar; 25(2):269-272. PubMed ID: 30761667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bæksted C; Nissen A; Pappot H; Bidstrup PE; Mitchell SA; Basch E; Dalton SO; Johansen C
    J Pain Symptom Manage; 2016 Aug; 52(2):292-7. PubMed ID: 27090851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients.
    Baeksted C; Pappot H; Nissen A; Hjollund NH; Mitchell SA; Basch E; Bidstrup PE; Dalton SO; Johansen C
    J Patient Rep Outcomes; 2017; 1(1):1. PubMed ID: 29757324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology.
    Sandler KA; Mitchell SA; Basch E; Raldow AC; Steinberg ML; Sharif J; Cook RR; Kupelian PA; McCloskey SA
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):44-52. PubMed ID: 30102201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
    J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer.
    Montemurro F; Mittica G; Cagnazzo C; Longo V; Berchialla P; Solinas G; Culotta P; Martinello R; Foresto M; Gallizioli S; Calori A; Grasso B; Volpone C; Bertola G; Parola G; Tealdi G; Giuliano PL; Aglietta M; Ballari AM
    JAMA Oncol; 2016 Apr; 2(4):445-52. PubMed ID: 26720497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Kluetz PG; Chingos DT; Basch EM; Mitchell SA
    Am Soc Clin Oncol Educ Book; 2016; 35():67-73. PubMed ID: 27249687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.
    Yoon J; Sim SH; Kang D; Han G; Kim Y; Ahn J; Oh D; Lee ES; Kong SY; Cho J; Mitchell SA
    J Pain Symptom Manage; 2020 May; 59(5):1082-1088.e6. PubMed ID: 32044423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.
    Basch E; Pugh SL; Dueck AC; Mitchell SA; Berk L; Fogh S; Rogak LJ; Gatewood M; Reeve BB; Mendoza TR; O'Mara AM; Denicoff AM; Minasian LM; Bennett AV; Setser A; Schrag D; Roof K; Moore JK; Gergel T; Stephans K; Rimner A; DeNittis A; Bruner DW
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):409-418. PubMed ID: 28463161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.
    Di Maio M; Gallo C; Leighl NB; Piccirillo MC; Daniele G; Nuzzo F; Gridelli C; Gebbia V; Ciardiello F; De Placido S; Ceribelli A; Favaretto AG; de Matteis A; Feld R; Butts C; Bryce J; Signoriello S; Morabito A; Rocco G; Perrone F
    J Clin Oncol; 2015 Mar; 33(8):910-5. PubMed ID: 25624439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
    Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
    JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial.
    Wintner LM; Giesinger JM; Sztankay M; Bottomley A; Holzner B;
    Trials; 2020 Oct; 21(1):849. PubMed ID: 33050917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
    Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
    Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
    McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
    Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer.
    Reeve BB; McFatrich M; Pinheiro LC; Freyer DR; Basch EM; Baker JN; Withycombe JS; Sung L; Mack JW; Waldron MK; Mowbray C; Palma D; Hinds PS
    J Pain Symptom Manage; 2017 Apr; 53(4):759-766. PubMed ID: 28062347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bruner DW; Hanisch LJ; Reeve BB; Trotti AM; Schrag D; Sit L; Mendoza TR; Minasian L; O'Mara A; Denicoff AM; Rowland JH; Montello M; Geoghegan C; Abernethy AP; Clauser SB; Castro K; Mitchell SA; Burke L; Trentacosti AM; Basch EM
    Transl Behav Med; 2011 Mar; 1(1):110-22. PubMed ID: 24073038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine Surveillance of Chemotherapy Toxicities in Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Wang TQ; Samuel JN; Brown MC; Vennettilli A; Solomon H; Eng L; Liang M; Gill G; Merali Z; Tian C; Cheng NYH; Campbell M; Patel D; Liu AX; Liu G; Howell D
    Oncol Ther; 2018 Dec; 6(2):189-201. PubMed ID: 32700029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE
    Minasian LM; O'Mara A; Mitchell SA
    Patient Relat Outcome Meas; 2022; 13():249-258. PubMed ID: 36524232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol.
    Krzyzanowska MK; Julian JA; Powis M; Howell D; Earle CC; Enright KA; Mittmann N; Trudeau ME; Grunfeld E
    BMC Cancer; 2019 Sep; 19(1):884. PubMed ID: 31488084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.
    Veitch ZW; Shepshelovich D; Gallagher C; Wang L; Abdul Razak AR; Spreafico A; Bedard PL; Siu LL; Minasian L; Hansen AR
    J Natl Cancer Inst; 2021 Aug; 113(8):980-988. PubMed ID: 33616650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.